Neumora Therapeutics Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

NMRA$0.50+3.3%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Financial Statements (Unaudited)Condensed Consolidated Balance Sheets

Condensed Cons olidated Balance Sheets

(in thousands)

	September 30,2024	December 31,2023
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$275,714	$374,038
Restricted cash	1,213	—
Short-term marketable securities	65,593	79,944
Prepaid expenses and other current assets	6,088	24,297
Total current assets	348,608	478,279
Long-term marketable securities	—	9,845
Property and equipment, net	1,297	1,790
Operating lease right-of-use assets	2,632	5,068
Restricted cash	—	1,213
Total assets	$352,537	$496,195
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$6,107	$337
Accrued liabilities	22,758	21,257
Early exercise liability, current portion	133	139
Operating lease liabilities, current portion	2,745	3,378
Total current liabilities	31,743	25,111
Operating lease liabilities, net of current portion	—	1,853
Early exercise liability, net of current portion	55	155
Total liabilities	31,798	27,119
Commitments and contingencies (Note 7)
Stockholders’ equity:
Common stock	16	16
Additional paid-in capital	1,209,020	1,172,570
Accumulated other comprehensive (gain) loss	105	(76)
Accumulated deficit	(888,402)	(703,434)
Total stockholders’ equity	320,739	469,076
Total liabilities and stockholders’ equity	$352,537	$496,195

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.